#CSHAsia # Genome Editing: All Things Considered
📍Suzhou, China | November 9-13, 2026
👉Register: www.csh-asia.org?content/3220

Our Invited Speaker List Has Been Updated! ⭐
#CSHAsia Meeting | Advances in Optical Interrogation of Living Cells and Organisms: Focus on the Brain
Suzhou, China | May 10–14, 2027
www.csh-asia.org?content/3278

#CSHAsia Meeting on Cell Death & Metabolism will be held November 15-19, 2027, in Suzhou, China.
Register now at the Early Bird rate before October 18, 2027!
www.csh-asia.org?content/3186

The transcription factor IRF8 drives tumor-specific exhaustion in CD8⁺ T Cells. From Marco Ongaro, Grégory Verdeil and colleagues: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

#CSHAsia Meeting on Microbiome and Barrier Immunity will be held October 25-29, 2027, in Suzhou, China.
Register now at the Early Bird rate before September 27, 2027!
www.csh-asia.org?content/3254
#Microbiome #Barrier Immunity #Infection #tumor

#CSHAsia Meeting | Genomics of Rare Diseases
📍 Suzhou, China
📅 September 20–24, 2027
Join leading researchers from around the world to explore the latest advances.
📣 Abstract submission is now open!
Submit your abstract by July 16, 2027, and share your research with the scientific community.

Intravesical mesothelin-based #CARTcells targeting MUC16 effectively control #BladderCancer in preclinical models. From Parwiz Abrahimi, Renier Brentjens, Jedd Wolchok, Taha Merghoub et al.: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

Great to be here in Suzhou 🇨🇳 this week for #CSHAsia Cancer Immunotherapy meeting. Looking forward to learning from colleagues and discussing science 👇

Updated Invited Speaker List!
#CSHAsia symposium on Novel Insights into Glia Function & Dysfunction, Suzhou, Nov. 30 - Dec. 4, 2026.
Register now for the early price before Oct. 30, 2026
www.csh-asia.org?content/2938
#glia #Microglia #Astrocyte #Oligodendrocyte, NG2 #CNS disorders

@ostendorflab.org, @immushuang.bsky.social, @sohailtavazoie.bsky.social et al. show that activation of LXRs elicits a T cell "pre-effector" state that enhances priming and promotes anti-tumor immunity. rupress.org/jem/article/...

In #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

#CSHAsia Meeting | Advances in Optical Interrogation of Living Cells and Organisms: Focus on the Brain
Suzhou, China | May 10–14, 2027

Join leading researchers to explore the latest advances in optical interrogation before March 5, 2027.
www.csh-asia.org?content/3278

Call for Abstracts! #CSHAsia # RNA Biology
📍Suzhou, China | Nov. 16-20, 2026
⌛️Abstract deadline due by Sept. 11, 2026
Early bird rate is available by Oct.16, 2026
👉checking more detailed information via www.csh-asia.org?content/3107

CD1d remodels the tumor-infiltrating myeloid populations controlling anti-tumor immunity. From Lauren Evans, Maria Conde Poole, Patricia Barral @barrallab.bsky.social: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

Targeting Mettl8-Tcf1 axis promotes CD8⁺ TPEX differentiation and antitumor immunity. From Jiaxi Song, Dan Cui, Qizhao Huang, Jia Li, Fengyin Li, and colleagues: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

Tumor-reactive LAG3⁺CD8⁺ T cells diverge into terminally exhausted cells and long-lived memory T cells. From Vaishali Aggarwal, Yangxi Sun, Chang Liu, Dario Vignali @vignalilab.bsky.social: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

PRECISE-seq reveals disease-relevant TCR repertoires with phenotypic plasticity. From Shibo Liu, Guanghao Liang, Yayun Yang, Yanyang Shi, Lihui Dong, Peng R. Chen, Meng Michelle Xu et al.: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

In this review, Almonte, Thomas, and Zitvogel highlight how the gut #microbiome modulates immune checkpoint blockade efficacy in #cancer. rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

T cell engagers emerge as a compelling therapeutic modality. A review from Baeuerle, Grieshaber-Bouyer, Sauer, and Michaelson: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

Ward, Kar, Balan & @bhardwajlab.bsky.social review how conventional cDC1s coordinate antitumor immunity through cross-presentation, immune cell networking, and spatial organization in tumors. rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia